2026 NPPES data Family Medicine Physician NPI 1902830557
Verify on CMS →

ROBERT POLOFSKY

Family Medicine Physician in AMITYVILLE, New York. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
8K
Medicare Part D claims · 471 beneficiaries · Family Medicine Physician avg: 3K
Generic prescribing
86%
generic claims · 14% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
90.8564/100
▲ 8 pts above national avg 83.1 · [object Object]
Industry payments
$1.2K
37 payments · CMS Open Payments (Sunshine Act)

What the federal data shows

ROBERT POLOFSKY reported a CMS MIPS final score of 90.8564/100 — above the 83.1 national average — and filed 8,254 Medicare Part D claims in 2023.

90.8564/100
MIPS score · +8 vs avg
8K
Part D claims, 2023
86%
generic prescribing
Likely
board-certified (heuristic)

Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.

ROBERT POLOFSKY's MIPS score vs every scored U.S. clinician

CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure

91 Top 40% higher than 60% of 477,587 scored providers

0–10: 8,684 scored providers (2%). Below this entry. 10–20: 3,008 scored providers (1%). Below this entry. 20–30: 3,069 scored providers (1%). Below this entry. 30–40: 2,746 scored providers (1%). Below this entry. 40–50: 2,928 scored providers (1%). Below this entry. 50–60: 5,882 scored providers (1%). Below this entry. 60–70: 13,906 scored providers (3%). Below this entry. 70–80: 118,074 scored providers (25%). Below this entry. 80–90: 129,887 scored providers (27%). Below this entry. 90–100: 189,403 scored providers (40%). This entry sits in this band. This provider 0 100 every MIPS-scored clinician, bucketed by value

Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Merit-based Incentive Payment System (MIPS) · 2023

Board certification likely (heuristic — not verified)

ROBERT POLOFSKY practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).

What does the federal data show about ROBERT POLOFSKY?

High performer (top quartile)

NPI registry status

Active

Issued 07/10/2006

NPI 1902830557

Primary specialty

Family Medicine Physician

High-volume

147,640 US NPIs in this specialty

Medicare Part D claims

8,254 141% vs specialty avg

2023 prescription claims

Specialty avg: 3,418

MIPS final score

90.8564/100 7.756399999999999% pts

Exceptional band

vs 83.1 national avg

Specialty distribution in New York

How Family Medicine Physician compares to other specialties among New York providers

New York providers

Family Medicine Physician share within New York

1. Family Medicine Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Family Medicine Physician share within New York

Medicare quality performance — MIPS

ROBERT POLOFSKY's 2023 MIPS final score plotted against the Family Medicine Physician national average

High performer (top quartile)
MIPS Final Score
90.8564/100
vs 83.1 national avg · 2023 performance year

MIPS final score (Family Medicine Physician) — 90.8564/100 vs national avg 83.1

0%100%National avg83%90.9%
MIPS final score (Family Medicine Physician) — 90.8564/100 vs national avg 83.1

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

ROBERT POLOFSKY appears in the CMS NPPES registry as a Family Medicine Physician provider at 221 BROADWAY SUITE 207, AMITYVILLE, NY, 11701, with a listed phone of (631) 598-0009. NPI 1902830557 was issued on 07/10/2006. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what POLOFSKY most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 8,254 prescription claims written by this provider, covering 471 Medicare beneficiaries and totaling roughly $1.4 million in drug spend, split 14% brand-name and 86% generic by claim count, with an opioid prescribing rate of 2.0%. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 90.8564/100 for the 2023 performance year (Quality 74.1454), compared with the national average of 83.1.

Family Medicine Physician is a high-volume specialty nationwide, with 147,640 enrolled providers across 56 states and an average of 3,418 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

221 BROADWAY SUITE 207
AMITYVILLE, NY 11701

Provider Details

NPI 1902830557
Specialty Family Medicine Physician
Gender Male
NPI Issued 07/10/2006

CMS Quality Score (MIPS)

Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.

90.8564
Final Score
Avg: 83.1
74.1454
Quality
100
Promoting Interoperability

Reporting: Alternative Payment Model

Industry payments received (2024) — CMS Open Payments transparency data

The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for ROBERT POLOFSKY. Source: openpaymentsdata.cms.gov.

Total received

$1.2K

Largest payer

Xeris Pharmaceuticals, Inc.

Most common payment type

Food and Beverage

Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.

License & disciplinary context — New York NYSBPMC 2023 annual report

Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~100K New York medical licensees in 2023 — they are NOT specific to ROBERT POLOFSKY. To verify ROBERT POLOFSKY's current license status, search the NYSBPMC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

312
Total board actions, New York 2023
Across 302 cases
3.12
Actions per 1,000 licensees
New York statewide rate
probation
Most common action type
89 cases

NYSBPMC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the New York disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Brand vs generic prescribing mix · Typical

ROBERT POLOFSKY — brand share 14.0%
Specialty average (est.)

14% brand-name claims vs 86% generic, on 8,254 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

8,254
Total Claims
$1.4M
Total Drug Cost
471
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
17,909
Total Day Supply
519,864
Brand vs Generic
14% brand / 86% generic
Brand Drug Cost
$1.1M
Generic Drug Cost
$202K
Opioid Claims
167 (2.0% rate)
Antibiotic Claims
236

Patient Demographics

Average Patient Age
72.1 years
Avg HCC Risk Score
1.23
Gender Split
57% female / 43% male
Age Distribution
<65: 70, 65-74: 205, 75-84: 147, 85+: 49

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

What ROBERT POLOFSKY prescribes most

Top Medicare Part D drugs by claim count, 2023

claims
Source CMS Medicare Part D Prescriber Public Use File As of 2023
Drug Claims
Atorvastatin Calcium
360
Amlodipine Besylate
332
Rosuvastatin Calcium
303
Montelukast Sodium
299
Losartan Potassium
247
Famotidine
223
Ozempic
Semaglutide
198
Metformin Hcl Er
Metformin Hcl
191
Pantoprazole Sodium
162
Ezetimibe
161

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Family Medicine Physician Overview

How ROBERT POLOFSKY fits within the Family Medicine Physician landscape nationally.

147,640
Family Medicine Physician Providers in US
56
States with Family Medicine Physician
3,418
Avg Claims per Provider

ROBERT POLOFSKY's 8,254 claims are above the specialty average of 3,418.

Nearby Family Medicine Physician Providers in New York

Other clinicians with the same primary specialty enrolled in New York, drawn from the same CMS NPPES roster as POLOFSKY.

Compare Family Medicine Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is ROBERT POLOFSKY's specialty?
ROBERT POLOFSKY specializes in Family Medicine Physician and practices in AMITYVILLE, New York.
How much does ROBERT POLOFSKY prescribe under Medicare Part D?
In 2023, ROBERT POLOFSKY wrote 8,254 Medicare Part D claims totaling $1.4M in drug costs for 471 beneficiaries.
What is ROBERT POLOFSKY's Medicare quality score?
ROBERT POLOFSKY has a CMS MIPS Final Score of 90.8564/100 (Quality: 74.1454). The national average MIPS Final Score is 83.1. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is ROBERT POLOFSKY located?
ROBERT POLOFSKY is located at 221 BROADWAY SUITE 207, AMITYVILLE, NY, 11701. Phone: (631) 598-0009.
What is ROBERT POLOFSKY's NPI number?
ROBERT POLOFSKY's National Provider Identifier (NPI) is 1902830557, issued on 07/10/2006.
Does ROBERT POLOFSKY prescribe more brand-name or generic drugs?
ROBERT POLOFSKY's prescribing is 14% brand-name and 86% generic drugs by claim count, with $1.1M in brand drug costs.
Does ROBERT POLOFSKY prescribe opioids?
Yes, ROBERT POLOFSKY had 167 opioid claims in 2023 with an opioid prescribing rate of 2.0%.
How many Family Medicine Physician providers are there in the US?
There are 147,640 Family Medicine Physician providers across 56 states in the US. The average Family Medicine Physician provider writes 3,418 Medicare Part D claims per year.
What drugs does ROBERT POLOFSKY prescribe most often?
Based on 2023 Medicare Part D data, ROBERT POLOFSKY's most frequently prescribed drugs include Atorvastatin Calcium, Amlodipine Besylate, Rosuvastatin Calcium. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does ROBERT POLOFSKY accept Medicare?
ROBERT POLOFSKY appears in CMS Medicare data with 8,254 Part D claims and 471 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify ROBERT POLOFSKY's credentials?
ROBERT POLOFSKY's NPI is 1902830557. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Quality Performance
CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology